9.2% Stake of Juno Therapeutics Inc (JUNO) Maintained by BAILLIE GIFFORD & COMPANY
BAILLIE GIFFORD & COMPANY
stated that they own 9.2% of Juno Therapeutics Inc (NASDAQ:JUNO) in a Form 13G/A disclosure that was filed with the Securities and Exchange Commission (SEC) on Wednesday, January 10th. The investor owns 10,547,798 shares of the stock valued at about $519,057,140. The filing is available through EDGAR at this link.
provided the following explanation of their ownership:
Other hedge funds and other institutional investors also recently modified their holdings of the company. The Manufacturers Life Insurance Company lifted its stake in shares of Juno Therapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after purchasing an additional 228 shares during the last quarter. Pacad Investment Ltd. purchased a new stake in Juno Therapeutics in the second quarter valued at about $105,000. Advisor Group Inc. raised its stake in Juno Therapeutics by 141.1% in the third quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,439 shares during the last quarter. QS Investors LLC purchased a new stake in Juno Therapeutics in the second quarter valued at about $135,000. Finally, Bronfman E.L. Rothschild L.P. raised its stake in Juno Therapeutics by 27,376.9% in the third quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 3,559 shares during the last quarter. Hedge funds and other institutional investors own 69.94% of the company’s stock.
In related news, CFO Steve Harr sold 8,750 shares of Juno Therapeutics stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $44.76, for a total transaction of $391,650.00. Following the transaction, the chief financial officer now owns 772,082 shares in the company, valued at $34,558,390.32. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Richard Klausner sold 36,000 shares of Juno Therapeutics stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $44.76, for a total value of $1,611,360.00. Following the transaction, the director now owns 744,392 shares in the company, valued at approximately $33,318,985.92. The disclosure for this sale can be found here. Insiders sold 65,956 shares of company stock worth $3,064,378 over the last ninety days. Corporate insiders own 15.08% of the company’s stock.
Shares of Juno Therapeutics Inc (NASDAQ JUNO) opened at $49.21 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77. The stock has a market capitalization of $5,610.00, a P/E ratio of -14.52 and a beta of 2.32. Juno Therapeutics Inc has a 12 month low of $18.90 and a 12 month high of $63.45.
Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.07. The firm had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The business’s revenue was up 115.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.57) earnings per share. research analysts predict that Juno Therapeutics Inc will post -4.02 EPS for the current fiscal year.
JUNO has been the subject of a number of research analyst reports. Raymond James Financial increased their price target on Juno Therapeutics from $45.00 to $61.00 and gave the company an “outperform” rating in a research note on Friday, November 3rd. Zacks Investment Research cut Juno Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Citigroup restated a “buy” rating and issued a $59.00 price objective on shares of Juno Therapeutics in a research note on Tuesday, October 31st. Wells Fargo & Co cut Juno Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, December 12th. Finally, Wedbush restated an “outperform” rating and issued a $64.00 price objective (up from $42.00) on shares of Juno Therapeutics in a research note on Thursday, November 2nd. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company. Juno Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $46.70.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.